S_ary In ovarian cancer patients a 6 kDa polypeptide, the tumour-associated trypsin inhibitor (TATI), can occur at elevated concentrations in both unrne and serum. In this study pretreatment serum levels of TATI (cut-off point 21 ngml-') and CA 125 (cut-off points 35Uml-' and 65Uml-') were determined in 152 patients with epithelial ovarian cancer (115 primary and 37 recurrent) and in 267 women with benign pelvic diseases. The data obtained were correlated with the tumour stage, histological type and tumour grade. Overall, TATI showed a sensitivity of 64% and a specificity of 75%. The sensitivity and specificity of CA 125 > 35 U ml-' were both 80%. Corresponding values for CA 125 > 65 U ml-' were 70% and 87%. The combination of the two markers increased the sensitivity to 91% (CA 125> 35 U ml-') and 86% (CA 125 > 65 U ml-'), while the specificity dropped to 61% and 68% respectively. TATI was clearly superior in mucinous carcinomas of the ovary, the rate of true-positive findings in these neoplasms was 67% vs 42% for CA 125 > 35 U ml-' and 33% for CA 125 > 65 U ml-'. Unlike With a sensitivity of more than 80%, the tumour marker CA 125 plays a major role in the detection and follow-up of ovarian cancer. In patients with malignant ovarian neoplasms another potential marker can, however, occur at elevated concentrations in both urine and serum: a 6 kDa polypeptide, the tumour-associated trypsin inhibitor TATI. Its structure is identical to that of PSTI, the pancreatic secretory trypsin inhibitor, which protects the pancreas from autodigestion Huhtala et al., 1982 Huhtala et al., , 1983 . As TATI suppresses both the tumour-associated isoenzymes TAT-1 and TAT-2 which may promote tumour invasion by activating prourokinase, it inhibits tissue destruction by trypsin (Koivunen et al., 1989) and is thus an indicator of the proteolytic activity of the tumour.
With a sensitivity of more than 80%, the tumour marker CA 125 plays a major role in the detection and follow-up of ovarian cancer. In patients with malignant ovarian neoplasms another potential marker can, however, occur at elevated concentrations in both urine and serum: a 6 kDa polypeptide, the tumour-associated trypsin inhibitor TATI. Its structure is identical to that of PSTI, the pancreatic secretory trypsin inhibitor, which protects the pancreas from autodigestion Huhtala et al., 1982 Huhtala et al., , 1983 . As TATI suppresses both the tumour-associated isoenzymes TAT-1 and TAT-2 which may promote tumour invasion by activating prourokinase, it inhibits tissue destruction by trypsin (Koivunen et al., 1989) and is thus an indicator of the proteolytic activity of the tumour.
While high TATI levels are present in the cyst fluid of both benign and malignant mucinous ovarian cysts, concentrations in serous fluids are elevated only in the presence of carcinoma. However, concentrations found in the cyst fluid do not correlate with the serum levels (Hahila et al., 1987) .
Elevated TATI levels have also been shown to be present in 90% of all pancreatic carcinomas and in 60-70% of gastrointestinal carcinomas (Haglund et al., 1986; Tomita et al., 1990) . In malignant ovarian neoplasms, TATI mainly appears to be useful for detecting mucinous carcinomas (Mogensen et al., 1990a , Torre et al., 1991 .
The purpose of this study was to determine whether TATI provides information other than that provided by CA 125 when used as a marker for epithelial carcinoma of the ovary.
Materials and metod
Between May 1988 and June 1993 serum levels of CA 125 and TATI were determined before laparotomy in 419 consecutive patients with epithelial carcinoma of the ovary (n = 152) or benign pelvic disease (n = 267). The patients were between 23 and 87 years of age (mean age 62.4 years). (Serov et al., 1973) and grading was performed according to Day et al. (1975) (Table I) .
As surgery is known to induce elevated serum levels, samples obtained within the first 4 weeks post-operatively were not considered (Matsuda et al., 1985) .
A cut-off point of 21 ng ml-l was defined for TATI. This was computed from the data obtained in 149 healthy women, which showed a distribution skewed to the right with a median of 12.9 ng ml-' and a mean of 13.8 ng ml-'. The 5th and the 95th percentiles were 7.6 and 21.1 ng ml-' respectively.
The 95th percentile of CA 125 in the 149 healthy women was 35.9Uml-' with a mean of 15.3 Uml-' and a median of 12.1 Uml-I. In accordance with the recommendation of the supplier, 35 U ml-' and 65 U ml1' were taken as cut-off points for CA 125 (Klug et al., 1984) .
The CA 125 assay was a radioimmunoassay obtained from Centocor (Malvern, PA, USA) and the TATI radioimmunoassay was obtained from Orion Diagnostica (Espoo, Finland). All assays were performed in duplicate.
Serum samples were collected before operation and treatment, divided into aliquots and stored at -20-C until tested. The study was conducted 'blind', i.e. sera were coded before being sent to the laboratory and the diagnosis revealed only after the sera were tested. (64) 122 (80) 107 (70) 139 (91) 131 (86) Tumour grade 1 32 11 (34) 17 (53) 13 (41) 23 (72) 19 (59) (> 35 U ml-l) and 89% (> 65 U ml-l) of recurrent tumours (Table I) .
TATI failed to show any correlation with the tumour stage. In fact, serum levels in patients with stage II, III and IV disease and in those with recurrent tumours did not differ significantly. Only patients with stage I disease were found to have clearly lower TATI levels (Table II) . One explanation for the high levels of TATI in stage H could be a value of 1317.7 ng ml-' in one patient. Excluding this sample, the mean value decreases to 72.2 ng ml-' and the median value to 35.7 ng ml-', with a standard deviation of 96 and a maximum of 300.3 ng ml'.
Analysis of the data by histological type showed tumourassociated trypsin inhibitor to be more efficient in mucinous tumours than CA 125. Its sensitivity in this histological type was 67% vs 42% for CA 125 > 35 U ml-' and 33% for CA 125>65 U ml-'. In serous carcinomas of the ovaries only 62% of the TATI levels were above the cut-off point compared with 84% for CA 125 > 35 U ml-' and 73% for CA 125 > 65 U ml-' (Table I ). In mucinous tumours the combination of the two markers did not produce any substantial benefits. But in all other carcinomas their combined use improved the sensitivity. Serum levels did not differ significantly between different histological types.
TATI levels correlated well with tumour grade: they were low in highly differentiated tumours, but clearly higher in poorly differentiated carcinomas (P<0.0001) (Table II) , and their sensitivity increased with decreasing differentiation. Serum levels above the cut-off point of 21 ng ml-1 were present in 34% of grade 1 tumours, in 57% of grade 2 tumours and in 80% of grade 3 tumours. In combination with CA 125, TATI correctly diagnosed poorly differentiated carcinomas in 100% (CA 125 cut-off 35 U ml-') and in 98% (cut-off 65 U ml-') of cases, (Table I ).
In the 267 women with benign pelvic disease the outcome of TATI assays was false positive in 25% of cases vs 22% and 13% for CA 125 > 35 U ml-' and CA 125 > 65 U ml-' respectively. Inflammatory conditions of the internal genital organs accounted most often for false-positive test outcomes (50% of the false-positive TATI findings vs 39% for both CA 125 > 35 U ml-' and CA 125 > 65 U ml-l). These were followed by endometriosis (29% vs 33% and 13% respectively). With the combined use of the two markers the rate of false-positive diagnoses was as high as 50% in patients with endometriosis. Ovarian hyperstimulation of patients seeking pregnancy was another common cause of increased tumour marker levels (45% for TATI vs 64% and 55% for CA 125) (Table MV) .
These figures add up to an overall sensitivity of 64% and an overall specificity of 75% for TATI. Depending on the cut-off level chosen, CA 125 showed sensitivities of 80% and 70% and specifcities of 80% and 87%. In combination, the two markers showed a sensitivity of 91 % and 86%. This improvement was, however, bought at the expense of a lower specificity (61% and 68%). But the combination showed an outstanding rate of true-negative findings (93% and 90% respectively) ( Table V) . ROC curves were constructed for each assay and a combination of the two markers (Figure 1 ). These curves show that CA 125 has greater sensitivity than TATI over all levels of specificity. Because of the independence of expression of TATI and CA 125, improved discrimination between benign and malignant tumours can be achieved by using both tests in combination. The ROC curves with a constant positive level for TATI of 21 ng ml-' or a constant level for CA 125 of 35 U nil-' show an increase of sensitivity with a specificity of no more than 76% (constant level for TATU) or 79% (constant level for CA 125) respectively.
Disaie-o
In this study the potential of TATI to predict the malignancy of pelvic tumours was evaluated and compared with that of CA 125. Because of its sensitivity of 70-80% and its specificity of 80-87%, CA 125 continues to be the most important marker in the preoperative diagnosis of pelvic tumours and in the detection of recurrent tumour growth. However, our data do not match the impressive results of 
